Effective use of ustekinumab for prepouch ileitis without improvement of concomitant pouchitis

Correspondence
  • 22 Downloads

Notes

Compliance with ethical standards

Conflict of interest

Niels Teich and Andreas Stallmach received advisory and lecture fees from Janssen.

Ethical approval

The present paper was exempt from approval.

Informed consent

Informed consent was obtained from the individual participant included in the study.

References

  1. 1.
    Samaan MA, de Jong D, Sahami S et al (2016) Incidence and severity of prepouch ileitis: a distinct disease entity or a manifestation of refractory pouchitis? Inflamm Bowel Dis 22:662–668CrossRefPubMedGoogle Scholar
  2. 2.
    Rottoli M, Vallicelli C, Bigonzi E et al (2018) Prepouch ileitis after ileal pouch-anal anastomosis: patterns of presentation and risk factors for failure of treatment. J Crohn’s Colitis.  https://doi.org/10.1093/ecco-jcc/jjx140 Google Scholar
  3. 3.
    Zaghiyan K, Kamiński JP, Barmparas G, Fleshner P (2016) De novo Crohn’s disease after Ileal pouch-anal anastomosis for ulcerative colitis and inflammatory bowel disease unclassified: long-term follow-up of a prospective inflammatory bowel disease registry. Am Surg 82:977–981PubMedGoogle Scholar
  4. 4.
    Bär F, Dietrich NA, Krause Tet al; German IBD Study Group (2018) Vedolizumab in the treatment of chronic, antibiotic dependent or refractory Pouchitis. Aliment Pharmacol Ther.  https://doi.org/10.1111/apt.14479
  5. 5.
    Tran-Minh ML, Allez M, Gornet JM (2017) Successful treatment with ustekinumab for chronic refractory pouchitis. J Crohn’s Colitis 11:1156CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Joint Internal Medicine Practice for Digestive and Metabolic DiseasesLeipzig and SchkeuditzLeipzigGermany
  2. 2.Internal Medicine Clinic IVUniversity ClinicJenaGermany
  3. 3.Faculty of MedicineFriedrich-Schiller UniversityJenaGermany

Personalised recommendations